ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NTLA / options
CLDX (29) NEOG (47) QDEL (21) ACHV (39) ⌘ Pro Terminal →

Intellia Therapeutics Inc. (NTLA) Options Positioning, Max Pain & Unusual Sweeps

$11.66 -6.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.50

Intellia Therapeutics Inc. (NTLA) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.75B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NTLA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NTLA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Intellia Therapeutics Inc. (NASDAQ: NTLA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.66 (-6.50% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NTLA ranks #922 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NTLA compare to CLDX and NEOG in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NTLA carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $2.36B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, NTLA leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NTLA?
▼

Per NTLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652130), Intellia Therapeutics Inc. generated $67.7M in revenue (+16.9% YoY), -$412.7M in net income, and -$395.9M in free cash flow against $842.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.50 (-1.36%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510025
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (9)SEC (8)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.8% Base Target
$19 Bull$10 Base$8 Bear
📬 FREE NTLA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NTLA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (25/100 Composite)
🔍 WHY NTLA SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (36% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (32% of score)

Altman Z-Score 1.17 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$11.91-0.6% Next Q
Q2 (-2Q)
30
Grade E$11.84+3.7% Next Q
Q3 (-1Q)
28
Grade E$12.28-5% Next Q
Current
25
Grade E$11.66-10.7% Hist 90D α
Trajectory: E (33) → E (25)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NTLA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NTLA currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.24) and Max Pain ($12.24) forces dealer call-delta covering toward $19.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NTLA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NTLA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 25%NO 75%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NTLA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NTLA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NTLA)

  • ✓Walkthrough of NTLA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NTLA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -15.93%▲ ASCENDING CHANNEL
2026-11-03O $13.23H $13.23L $11.66C $11.66VOL 4.09M
RES: $13.95SUP: $10.63SMA50: $12.24SMA200: $13.09
$19.06$16.65$14.23$11.82$9.40RES $13.95SUP $10.63$11.662026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NTLA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NTLA Butterfly Map → + Track NTLA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NTLA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NTLA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NTLA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NTLA)

Health Care Rank #922 of 1016 ⚔️ CLDX vs NTLA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NTLA vs. CLDX, NEOG, QDEL, ACHV)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Intellia Therapeutics Inc. (NTLA) ranks #922 by composite RQD confidence (25/100, grade E) and #277 by equity capitalization ($1.75B). Within this direct 5-issuer industry benchmark cohort, NTLA leads on earnings valuation at N/A trailing P/E, while NEOG leads on capital efficiency and profitability with -0.6% ROIC and 46.9% gross margin. NEOG currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NTLA at 25/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NTLA ACTIVE
Intellia Therapeutics Inc.
E 25/100 — — -35.0% -6.50% $1.75B Benchmark Subject
CLDX
Celldex Therapeutics Inc.
E 29/100 — 87.1% -35.0% -3.52% $2.36B /cldx-vs-ntla →
NEOG
Neogen Corporation
D 47/100 — 46.9% -0.6% 0.00% $2.58B /neog-vs-ntla →
QDEL
QuidelOrtho Corporation
E 21/100 — — -35.0% +5.89% $908.6M /qdel-vs-ntla →
ACHV
Achieve Life Sciences Inc.
D- 39/100 — — -35.0% -3.22% $702.8M /achv-vs-ntla →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001652130

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Intellia Therapeutics Inc. (NTLA) reported GAAP revenue of $67.7M (+16.9% vs. FY2024 revenue of $57.9M , and +86.5% cumulative change since FY2023) , GAAP net income of -$412.7M, operating cash flow of -$394.7M, and free cash flow of -$395.9M (-11.6% YoY). On the balance sheet, NTLA closed FY2025 with $842.1M in total assets against $0 in total debt (Altman Z-Score: 1.17, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $67.7M -$412.7M -$394.7M -$395.9M $842.1M —
FY2024 (FY) 2024-12-31 $57.9M -$519.0M -$348.9M -$354.7M $1.19B —
FY2023 (FY) 2023-12-31 $36.3M -$481.2M -$394.1M -$394.1M — —

3. NTLA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NTLA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Intellia Therapeutics Inc. (NASDAQ: NTLA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.66 (-6.50% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NTLA ranks #922 in composite RQD confidence.

How does NTLA compare to CLDX and NEOG in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NTLA carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $2.36B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, NTLA leads on earnings multiple (N/A) while NEOG leads on capital efficiency (-0.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NTLA?

Per NTLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652130), Intellia Therapeutics Inc. generated $67.7M in revenue (+16.9% YoY), -$412.7M in net income, and -$395.9M in free cash flow against $842.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NTLA trading relative to its 50-day, 200-day, and 52-week technical levels?

NTLA last traded at $11.66 (-6.50% on volume of 3,884,550 shares), positioning the stock -4.74% below its 50-day simple moving average ($12.24) and -10.92% below its 200-day simple moving average ($13.09). Across its 52-week range of $7.95 to $18.48, NTLA sits at the 35.2% percentile with a 14-day RSI of 52.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.20 to $13.12).

Direct Sub-Reports: NTLA RQD Cockpit NTLA 12M Forecast NTLA Earnings & Move NTLA Dividends & DRIP NTLA Insiders & 13F NTLA Whale Options NTLA Profit Sankey NTLA News & Why
ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

NTLA — Intellia Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Intellia Therapeutics Inc. (NTLA) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $11.66 (-6.50% 1D, market capitalization $1.75B).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -21.35%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.17, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Intellia Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry,. The company reported revenue of $67.7M for FY 2025 and $57.9M for FY 2024, indicating a revenue base that is small relative to its reported operating losses.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Intellia Therapeutics Inc. (NTLA) reported $67.7M in annual revenue (up from $57.9M in FY2024, +16.9% YoY) and -$412.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($36.3M revenue, -$481.2M net income) through FY2025, NTLA scaled operating cash flow to -$394.7M and free cash flow to -$395.9M, backed by $842.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -21.35% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $7.95 – $18.48 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream dependencies, no sector correlations, and no bottleneck links recorded.

  • Key Question #1: Can NTLA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $67.7M and free cash flow of -$395.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NTLA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NTLA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Intellia Therapeutics Inc. (NTLA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NTLA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NTLA Bull vs. Bear Conversation Board — What's Your Call at $11.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NTLA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NTLA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $15.46 (+24.0%)
📌 Pinned Debate

The stock is up 7.6% on positive late-stage trial data for a gene-editing therapy, and institutional whale flow scores 12 of 20, the st

Here is why I am bullish on NTLA here at $12.47: The stock is up 7.6% on positive late-stage trial data for a gene-editing therapy, and institutional whale flow scores 12 of 20, the strongest RQD pillar.. Compare NTLA's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $11.85 are getting bought.

CapAlloc_Nerd 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: In Vitro & In Vivo Diagnostic Substances. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $9.60 (-23.0%)
Spot @ $12.47

With ROIC at -35%, FCF yield at -21.35%, and an Altman Z-Score of 1.17, the company is burning cash faster than its $155.5M cash balanc

I respect the product at Intellia Therapeutics Inc., but the stock at $12.47 is a different story. With ROIC at -35%, FCF yield at -21.35%, and an Altman Z-Score of 1.17, the company is burning cash faster than its $155.5M cash balance can comfortably support.. FCF yield is -21.35% and RQD sits at 25/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%